Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 12, 2000, Pages 2-8

  Fisher, R I ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXAN; IBRITUMOMAB TIUXETAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; RITUXIMAB; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

ADULT; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDUCED DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERONS; LYMPHOMA, NON-HODGKIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 0034467371     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Natinal Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage
2. Perspective: A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group
3. Combination chemotherapy in non-Hodgkin's lymphoma: Results of long-term followup
4. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmmunotherapy
5. The natural history of initially untreated low-grade non-Hodgkin's lymphoma
6. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: Preliminary results of a prospective trial
7. Therapy of advanced lymphocytic lymphoma: A preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy
8. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma
9. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
10. A meta-analysis of randomised trials evaluating the role of interferon as treatment for follicular lymphoma
11. Alpha-interferon consolidation following intensive chemotherapy does not prolong the progression-free survival of patients with low grade non-Hodgkin's lymphoma: Results of Southwest Oncology Group, randomized phase III study 8809
12. Interferon-alfa2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress
13. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: A preliminary report of an intergroup trial (CALGB 8691 and EST 7486)
14. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
15. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
16. Radioimmunotherapy of B-cell lymphoma with [131 I] anti-B1 (anti-CD20) antibody
17. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
18. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
19. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte
20. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma
21. SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy
22. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
23. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
24. Randomized comparison of MACOP-B and CHOP in patients with intermediate grade non-Hodgkin's lymphoma
25. A predictive model for aggressive non-Hodgkin's lymphoma
26. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACECytaBOM
27. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
28. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
29. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
30. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
31. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
32. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
33. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group
34. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients with aggressive lymphomas: Updated results of the randomized LNH93-3 study